Healios K.K. (TYO:4593)

Market Cap	60.62B +132.5%
Revenue (ttm)	104.00M -81.4%
Net Income	-2.22B
EPS	-20.59
Shares Out	135.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,865,800
Average Volume	3,422,860
Open	417.00
Previous Close	420.00
Day's Range	411.00 - 452.00
52-Week Range	194.00 - 747.00
Beta	1.55
RSI	61.84
Earnings Date	Feb 16, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 65
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4593

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.